Estrogen receptor beta is an important modulator of hormone-related carcinogenesis in the human prostate.
雌激素受体β是人类前列腺激素相关癌变的重要调节剂。
基本信息
- 批准号:MR/L00156X/1
- 负责人:
- 金额:$ 24.22万
- 依托单位:
- 依托单位国家:英国
- 项目类别:Fellowship
- 财政年份:2013
- 资助国家:英国
- 起止时间:2013 至 无数据
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Prostate cancer is the most common cancer in men, with 214 new cases diagnosed per 1000 men in Europe. Currently, it is the second most common cause of cancer-related death in men.The development of prostate cancer is largely dependent on the male hormone, testosterone and so for many patients initial treatment of the disease involves blocking the production and activity of testosterone in order to suppress the disease. Unfortunately, for many men the cancer subsequently becomes resistant to this treatment and continues to grow in the absence of testosterone. Current chemotherapy treatments are not particularly effective against this hormone resistant prostate cancer (HRPC) and patients survive for an average period of 18 months from the time of HRPC diagnosis.In females, the dominant hormone is estrogen. Estrogen is known to play an important role in the development and growth of breast and ovarian cancers in women. Consequentially, a number of treatments for these diseases are aimed at blocking the production and activity of estrogen in a manner analogous to hormone deprivation treatment of prostate cancer. Estrogen is also present in smaller quantities in men where it regulates a variety of processes in the body. It does this by sending signals to cells using the estrogen receptor. When activated, the estrogen receptor instructs the cell's genetic code (DNA) to create proteins, which in turn influence the behaviour of the cancer cell in a particular way. Recent scientific research has demonstrated that estrogen and one of its receptors, estrogen receptor beta (ERb) play an important role in controlling some of the genetic mechanisms that can give rise to prostate cancer. However, the mechanisms by which ERb regulates cancer-related genes are poorly characterised. In particular, it is thought that when prostate cancer becomes resistant to testosterone deprivation to become HRPC, estrogen may continue to provide a stimulus for cancer growth acting via the estrogen receptor.In my research, I aim to increase understanding of how estrogen and ERb can regulate cancer-related genes in the prostate. I will be studying the effects of estrogen and ERb in order to understand how prostate cancer initially develops and how it becomes resistant to testosterone deprivation. Estrogen receptors are dependent upon a protein in the cell called FoxA1, which acts as bridge to bind the receptor to the DNA enabling it to switch genes on and off. Most of our understanding of FoxA1 and its influence on estrogen receptors comes from the study of breast cancer. At present, it has not been determined if FoxA1 has any function with respect to estrogen receptor in the prostate. By increasing or decreasing levels of FoxA1 in prostate cells and tissue I will explore the role that it plays in the prostate and determine whether it could be a potential drug target to control the progression of prostate cancer.The research will be conducted in the laboratory using cells derived from human prostate cancer tissue as these provide a useful model for studying the disease. I also aim to study prostate tissue obtained from patients undergoing surgery who have given permission for me to do so, in order to see whether some of the findings observed in the cells are also present in 'real-patient' samples.By increasing the understanding of how estrogen influences the development and progression of prostate cancer I aim to find new ways to treat HRPC.
前列腺癌是男性最常见的癌症,在欧洲,每1000名男性中就有214名新确诊病例。目前,前列腺癌是男性癌症相关死亡的第二大常见原因。前列腺癌的发生在很大程度上依赖于男性激素和睾酮等,因此对许多患者来说,最初的治疗包括阻断睾酮的产生和活性,以抑制疾病。不幸的是,对于许多男性来说,癌症后来对这种治疗产生了抗药性,并在缺乏睾丸素的情况下继续生长。目前的化疗方法对这种激素抵抗型前列腺癌(HRPC)并不是特别有效,患者从HRPC确诊之日起平均存活18个月。在女性中,主要的激素是雌激素。众所周知,雌激素在女性乳腺癌和卵巢癌的发展和生长中发挥着重要作用。因此,针对这些疾病的一些治疗方法旨在阻断雌激素的产生和活性,类似于前列腺癌的激素剥夺治疗。在男性体内,雌激素的含量也较少,它可以调节体内的各种过程。它通过使用雌激素受体向细胞发送信号来做到这一点。当被激活时,雌激素受体指示细胞的遗传密码(DNA)产生蛋白质,这些蛋白质反过来以特定的方式影响癌细胞的行为。最近的科学研究表明,雌激素及其受体之一雌激素受体β(ERb)在控制前列腺癌发生的某些遗传机制中发挥着重要作用。然而,ERb调控癌症相关基因的机制尚不清楚。特别是,人们认为,当前列腺癌对睾丸激素缺乏产生抵抗力,成为HRPC时,雌激素可能会通过雌激素受体继续为癌症的生长提供刺激。在我的研究中,我的目标是增加对雌激素和ERb如何调节前列腺癌相关基因的理解。我将研究雌激素和ERb的作用,以了解前列腺癌最初是如何发展的,以及它是如何对睾丸激素缺乏产生抵抗力的。雌激素受体依赖于细胞中一种名为FoxA1的蛋白质,它起到将受体与DNA结合的桥梁作用,使其能够开关基因。我们对FoxA1及其对雌激素受体的影响的大部分了解来自于对乳腺癌的研究。目前,还没有确定FoxA1是否与前列腺中的雌激素受体有关。通过增加或降低前列腺细胞和组织中FoxA1的水平,我将探索它在前列腺中所起的作用,并确定它是否可能成为控制前列腺癌进展的潜在药物靶点。这项研究将在实验室进行,使用来自人类前列腺癌组织的细胞,因为这些细胞为研究疾病提供了有用的模型。我的目标也是研究从手术患者那里获得的前列腺组织,这些患者得到了我的许可,以了解在细胞中观察到的一些发现是否也存在于真正的患者样本中。通过增加对雌激素如何影响前列腺癌的发展和进展的理解,我的目标是找到治疗高密度前列腺癌的新方法。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.
- DOI:10.1016/j.eururo.2015.10.042
- 发表时间:2016-08
- 期刊:
- 影响因子:23.4
- 作者:Shaw GL;Whitaker H;Corcoran M;Dunning MJ;Luxton H;Kay J;Massie CE;Miller JL;Lamb AD;Ross-Adams H;Russell R;Nelson AW;Eldridge MD;Lynch AG;Ramos-Montoya A;Mills IG;Taylor AE;Arlt W;Shah N;Warren AY;Neal DE
- 通讯作者:Neal DE
Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity.
- DOI:10.1016/j.mce.2016.11.016
- 发表时间:2017-01-15
- 期刊:
- 影响因子:4.1
- 作者:Nelson AW;Groen AJ;Miller JL;Warren AY;Holmes KA;Tarulli GA;Tilley WD;Katzenellenbogen BS;Hawse JR;Gnanapragasam VJ;Carroll JS
- 通讯作者:Carroll JS
ERß-mediated induction of cystatins results in suppression of TGFß signaling and inhibition of triple-negative breast cancer metastasis.
ERα 介导的半胱氨酸蛋白酶抑制剂的诱导导致 TGFα 信号传导的抑制和三阴性乳腺癌转移的抑制。
- DOI:10.17863/cam.41819
- 发表时间:2018
- 期刊:
- 影响因子:0
- 作者:Reese J
- 通讯作者:Reese J
Applying for research funding. Part 1 - sources of funding.
申请研究经费。
- DOI:10.1177/2051415815626322
- 发表时间:2016
- 期刊:
- 影响因子:0.3
- 作者:Nelson A
- 通讯作者:Nelson A
Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity
对癌细胞系模型和组织中雌激素受体β抗体的综合评估揭示了试剂特异性的关键局限性
- DOI:10.17863/cam.8740
- 发表时间:2017
- 期刊:
- 影响因子:0
- 作者:Nelson A
- 通讯作者:Nelson A
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Adam William Nelson其他文献
Adam William Nelson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似国自然基金
盐皮质激素受体抑制2型固有淋巴细胞活化加重心肌梗死后心室重构的作用机制
- 批准号:82372202
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
GREB1突变介导雌激素受体信号通路导致深部浸润型子宫内膜异位症的分子遗传机制研究
- 批准号:82371652
- 批准年份:2023
- 资助金额:45.00 万元
- 项目类别:面上项目
多囊卵巢综合征中甲酰肽受体2调控小胶质细胞代谢重编程导致GnRH神经元过度激活及HPO轴异常的病理机制研究
- 批准号:82370797
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
G蛋白偶联受体GPR110调控Lp-PLA2抑制非酒精性脂肪性肝炎的作用及机制研究
- 批准号:82370865
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
骨骼肌中胰高血糖素受体的表达及其调控血糖稳态的作用与机制研究
- 批准号:82370820
- 批准年份:2023
- 资助金额:49.00 万元
- 项目类别:面上项目
Succinate-Succinate Receptor介导的代谢反应在正畸牙根吸收中的作用
- 批准号:82371007
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
Leptin receptor阳性细胞通过分泌Hedgehog蛋白调控椎间盘退变及修复的谱系研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
细胞骨架对鞭毛敏感蛋白FLS2胞吞及其免疫调控机制的研究
- 批准号:32000483
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
FAM134B的乙酰化修饰在内质网自噬中的功能研究
- 批准号:32000521
- 批准年份:2020
- 资助金额:16.0 万元
- 项目类别:青年科学基金项目
双氢喋啶还原酶通过重塑蛋白质亚硝基化修饰促进线粒体自噬
- 批准号:32000519
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
The role of estrogen receptor alpha in prostatic fibrosis contributing to benign prostatic hyperplasia
雌激素受体α在导致良性前列腺增生的前列腺纤维化中的作用
- 批准号:
10607151 - 财政年份:2023
- 资助金额:
$ 24.22万 - 项目类别:
Development of Potent Estrogen Receptor Beta Agonists for Treating Glioblastoma
开发用于治疗胶质母细胞瘤的有效雌激素受体β激动剂
- 批准号:
10594832 - 财政年份:2023
- 资助金额:
$ 24.22万 - 项目类别:
Estrogen-mediated immune regulation in human and experimental inflammatory bowel disease
人类和实验性炎症性肠病中雌激素介导的免疫调节
- 批准号:
10853530 - 财政年份:2023
- 资助金额:
$ 24.22万 - 项目类别:
Sexual dimorphism and the immuno-modulatory role of estrogen signaling in HNSCC
HNSCC 中雌激素信号的性别二态性和免疫调节作用
- 批准号:
10751465 - 财政年份:2023
- 资助金额:
$ 24.22万 - 项目类别:
Estrogen and its Receptor in Intraocular Pressure Regulation
雌激素及其受体在眼压调节中的作用
- 批准号:
10595307 - 财政年份:2023
- 资助金额:
$ 24.22万 - 项目类别:
Establishing sex-specific mechanisms for estrogen receptor beta in heroin extinction memory recall
建立海洛因灭绝记忆回忆中雌激素受体β的性别特异性机制
- 批准号:
10678227 - 财政年份:2023
- 资助金额:
$ 24.22万 - 项目类别:
Role of Estrogen Receptors and Neurohypophyseal Gene Expression in Vasopressin Release in a Model of Dilutional Hyponatremia
稀释性低钠血症模型中雌激素受体和神经垂体基因表达在加压素释放中的作用
- 批准号:
10389144 - 财政年份:2022
- 资助金额:
$ 24.22万 - 项目类别:
Therapeutic targeting a membrane estrogen receptor with a novel non-steroidal compound for Alzheimer's disease
使用新型非甾体化合物靶向膜雌激素受体治疗阿尔茨海默病
- 批准号:
10670490 - 财政年份:2022
- 资助金额:
$ 24.22万 - 项目类别:
The Role of Estrogen Receptor Alpha Variant Size and Localization in Modulating TLR7-Induced Inflammation
雌激素受体 α 变体大小和定位在调节 TLR7 诱导的炎症中的作用
- 批准号:
10571915 - 财政年份:2022
- 资助金额:
$ 24.22万 - 项目类别:
The Role of Estrogen Receptor Alpha Variant Size and Localization in Modulating TLR7-Induced Inflammation
雌激素受体 α 变体大小和定位在调节 TLR7 诱导的炎症中的作用
- 批准号:
10365365 - 财政年份:2022
- 资助金额:
$ 24.22万 - 项目类别: